Figure S2 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

Key Points

• Effective treatment strategy targets pancreatic cancer with MTAP deletion using PRMT5 and KRAS inhibitors.
• In vivo analysis demonstrates significant efficacy in treatment, suggesting potential for broader application in cancer therapy.
• Utilizing combined inhibitors aims to overcome challenges in treating KRAS-mutant pancreatic cancer, demonstrating new therapeutic avenues.
• Further research may validate this combined strategy in clinical settings, highlighting its importance for addressing treatment-resistant cancer types.

Abstract